Nucleotide Sequence of Gene Encoding Capsid Protein VP1 of Foot-and-Mouth Disease Virus/Type O₁ Iran

Masoudi*¹, S., Khedmati, K.², Parvin Ashtiani, M.³, Khorasani, A., Shahsavandi, S.⁴ and Sadri, R.²

- 1. Poultry Vaccines Research & Production Dept., Razi Vaccine & Serum Research Institute,
 P.O.Box 11365-1558, Tehran, Iran
 - 2. Animal Viral Diseases Research & Diagnosis Dept., Razi Institue
 3. Biotechnology Dept., Razi Institue
 - 4. Foot-and-Mouth Disease vaccine Research & Priduction Dept., Razi Institue
 Received 19 Nov 2002, accepted 24 Apr 2003

Summary

VP1 protein of foot-and-mouth disease virus (FMDV) contains the immonogenic hypervariable region of the virus. The antigenic variation in FMDV is particularly related to the difference between nucleotide and amino acid sequences of capsid protein. On the basis of this phenomenon, type diagnosis of FMDV can be done by the polymerase chain reaction (PCR). In order to specifically identify the O₁ FMDV serotype of Iran the complete coding sequence of its VP1 protein was amplified by RT-PCR, and nucleotide and amino acid sequences of the PCR product were determined. The nucleotide and deduced amino acid sequence exhibited 84% and 88% homology with the VP1 region of serotype O₁K, respectively.

Keyword: foot-and-mouth disease virus, O₁/Iran, VP1, sequence, RT-PCR

Introduction

Foot-and-mouth disease virus (FMDV), an aphtovirus, is a member of *Picornaviridae* family and causes a highly contagious and debilitation disease of cloven-hoofed animals such as cattle, sheep, goats and others. The disease is

^{*}Author for correspondence. E-mail: masoudi@rvsri.com

widespread in many parts of the world and is the most economically important viral disease of live stock (Murphy *et al* 1999).

FMDV consist of a single stranded RNA molecule of positive sense and four capsid proteins (VP1-VP4) (Rueckert 1996). Like many other RNA viruses, FMDV has a high mutation rate, particularly in VP1 gene, and in the range of 10³-10⁴ substitution per nucleotide and RNA doubling (Dopazo et al 1988). Mutations are generated during genome replication by the viral replicase owing to lack of proof reading activity (Stram et al 1994). Therefor FMDV genome is highly variable; this variation leads to antigenic diversity and occurrence of seven different serotype (A, O, C, SAT1-SAT3, and Asia1) and many subtypes (Murphy et al 1999, Rueckert 1996). Hypervaiable region of FMDV genome that is responsible for this antigenic diversity lie in the VP1 gene segment (Acharya et al 1989, Bittle et al 1982, Dopazo et al 1988, Grubman et al 1993, Strohmaier et al 1982). Therefor FMDV antigenic diversity is due to nucleotide and amino acid substitution of VP1 (Beck et al 1987). This sequence diversity can be used in FMDV type diagnosis by RT-PCR (Callens et al 1997, Locher et al 1995, Reid et al 1998). In addition VP1 sequence determining would provide useful data about virus antigenicity (Stram et al 1994, Beck & Strohmaier 1987, Tularsiram et al 1997). Nucleotide sequence of the VP1 coding region of FMDVs of each of the seven serotype are now known to permit identification of the molecular basis for type and subtype classification of FMDV (Dopazo et al 1988). One of the main FMDV serotype that infects livestock in Iran is O₁. Here we describe the complete nucleotide and amino acid sequences of the VP1 encoding region of the FMDV type O₁/Iran genome. Morover, the relationship of the serotype to other O₁ FMDV serotypes was examined.

Materials and Methods

Virus. The seventh passage of FMDV type O₁/Iran was obtained from foot-and-mouth disease department, Razi Institute. The virus isolated from toungue epithelia

of affected cattle in East Azarbaijan province and named $O_1/95$. It was propagated in BHK-21-C13 cells.

RNA. Total RNA was extracted from 500µl of FMDV infected cell suspension as previously described (Masoudi *et al* 2000).

Oligonucleotide primer. Sense and antisense primers noted previously (Masoudi *et al* 2000). cDNA synthesis was primed with a primer complementary to the 3' end of the 1D (nucleotide sequence coding for VPI protein) coding sequence, nucleotide 3526-3502. Sense primer was also derived from the 5'end of 1D sequence nucleotide 2886-2903. The number indicates the position of nucleotide in VPI of O₁K (Kurze *et al* 1981).

RT-PCR and cloning. The RT-PCR condition and cloning of PCR product have been previously described (Masoudi *et al* 2000). Briefly, complete double stranded cDNA of 1D sequence was synthesized. The PCR product was purified from low melting point agarose gel as described by Sambrook *et al* (1989) and inserted by cohesive end ligation into *EcoRI-NdeI* site of pEt-23a+ vector. To sequence the insert the fluorescent dye deoxy-terminator system was used with the T7 promoter primer.

Serotype relationship. The relationship of O₁/Iran serotype to other O FMDV serotypes was examined on the basis of the amino acide and nucleotide sequenses of VP1. In this regard ten FMDV coding-regions were aligned and sequence base pair smilarity of them were determined.

Results

Nucleotide sequence of VP1 gene. The total length of the amplified product as per the sequense is 639bp, which correspond to the 1D segment of O₁ genome that encodes capcid protein VP1 (Figure 1). Amplification was specific because no other nonspecific product was seen in the gel. The G+C content of amplified product of

O₁/Iran was 55.74%. The VP1 segment of O₁ serotype encodes a 639bp amino acid protein (Figure 2). The nucleotide sequence was analyzed for restriction enzyme site using computer program DNasis. There was one conserved *BstEII* site at position 436.




Figure 1. The PCR product from enzymatic amplification of FMDV type O_i/Iran. Lane 1: 100bp DNA ladder, lane 2: FMDV type O_i/Iran that repeated on lanes 3 and 4

Serotype relationship examination. The phylogenic relationship dendrogram of eleven FMDV sequences through alignment analysis of VP1 nucleotide sequences, and sequence pair distance of them were shown in figures 3 and 4. Comparison of the VP1 nucleotide sequence of O₁/Iran with O₁K (as standard virus) showed that the homology between their VP1 genes is 81.1%. The dendogram shows that the rate of nucleotide substitutions between the O₁/Iran gene and the O₁K is of 19.

Deduced amino acid sequence. The derived amino acid sequence showed that the C-terminal half of total charge is approximately +11 which confirms the earlier reports that VP1 FMDV is basic in nature. Comparsion between amino acid

sequence of VP1 O_1 /Iran with other O_1 types revale that the main alternations in amino acid sequence are located in the major antigenic domain of VP1 (Figure 5). Comparison of amino acid sequence of VP1 O_1 /Iran with that of O_1 K exhibited 88.7% sequence homology (Figure 6).

S A G E S A D P V T A T V E N Y G G 20 CCACTTCTGCGGGCGAGTCGGCTGACCTGTGACTGCCACTGTTGAGAACTATGGCGGT TQVQRRQHTDVSFI 61 GAGACACAAGTCCAAAGGCGTCAACACACAGACGTCTCGTTTATATTAGACAGATTTGTG K V T P K D Q I N V L D L M Q T P A H T 60 121 AAAGTGACACCAAAAGACCAAATTAACGTACTGGACTTGATGCAAACCCCCGCCCACACT V G A L L R A A T Y Y F A D L E V 181 TTGGTGGGCGCGCTCCTCCGCGCTGCCACTTACTACTTTGCTGACCTGGAGGTTGCAGTT LALPYKHEGNLTWVPNGAP 241 AAACACGAGGGAAACCTCACCTGGGTCCCGAACGGGGCGCCTGAGAAGGCGTTGGATAAC E K A L D N T T N P T A Y H K A P L T T 301 ACCACCAACCCAACAGCATACCACAAGGCACCGCTCACCCGGCTTGCACTGCCTTACACG A P H R V L A T V Y N G N C R Y G E G P 140 361 GCACCACACCGTGTGTTGGCTACTGTTTACAACGGGAACTGTAGGTACGGTGGAGGCCCT V A A V R G D L Q V L T Q K A A RTLP 421 GTGGCCGCTGTGAGAGGTGACCTGCAAGTGTTGACCCAGAAGGCGGCTAGAACGCTGCCT S F N Y G A I K A T R V T E L L Y R M 180 481 ACCTCCTTCAACTACGGTGCTATCAAGGCTACACGGGTGACTGAACTGCTTTACCGCATG A E T Y C P R P L L A I H P S G A R 200 540 AAGAGGGCTGAGACATACTGCCCCCGGCCTCTTTTGGCCATTCACCCGAGCGGAGCCAGA H K Q K I V A P V K Q T L 213 601 CACAAGCAAAAGATCGTGGCACCGGTGAAACAGACTTTG

Figure 2. The complete nucleotide sequence of the coding region of VPI protein of FMDV type O₁/Iran





Figure 3. Phylogenic relationship dendogram of 11 FMDV O₁ sequenses through alignment analysis of VP1 nuclotide sequense. The number indicates the rate of nucleotide substitution

Percent Similarity												
	1	2	3	4	5	6	7	8	9	10		
1		100.0	93.3	92.5	87.5	80.3	88.8	93.1	87.4	92.8	1	BAHRAIN.SEQ
2	0.0		93.3	92.5	87.5	60.3	86.8	93.1	87.4	92.8	2	EMARAT.SEQ
3	6.6	6.6		92.1	87.7	80.4	88.9	93.0	87.9	92.7	3	GEORGIA SEQ
4	7.2	7.2	7.5		87.5	79.7	88.9	97.7	87.7	96.7	4	IRQ.SEQ
5	12.5	12.5	12.0	12.0		81.1	88.0	87.7	91.1	68.0	5	O1IRAN.SEQ
6	19.7	19.7	19.4	20.1	19.2		80.8	79.8	79.8	80.3	6	O1K.SEQ
7	11.0	11.0	10.9	10.4	11.8	19.1		88.6	86.6	89.1	7	RUSS.SEQ
8	6.4	6.4	6.5	1.6	11.7	19.8	10.6		87.8	97.2	8	SAU.SEQ
9	12.1	12.1	11.5	11.5	8.3	19.7	12.7	11.5		88.2	9	TUR.SEQ
10	7.2	7.2	7.2	3.0	12.0	19.7	10.7	2.4	11.3		10	UKG.SEQ
	1	2	3	4	6	6	7	8	9	10		

Figure 4. Sequence pair distances of 11 FMDV O1 nucleotide sequences

	TTSTGESADP	VTATVENY	GGETQVQRR	HTDVSFILD	RFVKVTPKDQI	N V Majority
	10	0	20	30	40	50
1	TTSTGESADP	VTTTVENY	GGETOVORRO	HIDVSFILD	REVKVTPKDOI	N V BAHRAIN.PE
1					RFVKVTPKDQI	
1	TTSTGESADP	VTATVENY	GGETQVQRR	HTDVSFILD	RFVKVTPKDPI	T V GEORGIA.PF
1	TTSTGESADP	VTATVENY	GGETQVQRR	HTDVSFILD	RFVKVTPKDQI	N V INDIA.PRO
1					RFVKVTPKDQI	
1					R F V K V T P K D Q I	
1	TTSAGESADP	·VITTVENY	G G E T Q T Q R R (2 H T D V S F I M D	R F V K V T P Q N Q I I	N I Olk. PRO
1					REVKVTPKDQI	
1					RFVKVTPKDQI	
1					RFVKVTPKDQI	
1	TTSAGESADE	VTATVENY	GGETQVQRR	OHTDVSFILD	RFVKVTPKDQI	N V UKG. PRO
	LDLMOTPAHT	LVGALLRT	ATYYFADLE'	/AVKHEGNLT	WVPNGAPETAL	D N Majority
		-	- , 	T		
	61	.0	70	80	90	100
51						D N BAHRAIN.PF
51					WVPNGAPETAL	
51					WVPNGAPETAL	
51					WVPNGAPENAL	
51 51					W V P N G A P E T A L W V P N G A P E K A L	
51					WVPNGAPEKAL	
51					W V P N G A P E T A L	
51					WVPNGAPETAL	
51					WVPNGAPEAAL	
51					N V P N G A P E T A L	
						D I DIGITIO
	TTNPTAYHKA	APLTRLALF	YTAPHRVLA	TVYNGNCKYG	ESPVTNVRGDL	Q V Majority
	11	10	120	130	140	150
101	TTNPTAYHKA	A P I. T R I. A I. P	YTAPHRVLA	TVYNGIDICKYG	ESAVTNVRGDL	O V BAHRAIN PE
					ESAVTNVRCDL	
					ESSVTNVRGDL	
					DGSVTNIRGDL	
					ESPVTNVXGDL	
101	. TTNPTAYHKA	APLTRLALE	YTAPHRVLA	TVYNGNCRIYG	EGPVAAVRGDL	O V Oliran, PRC
101	TTNPTAYHKA	APLTRLALF	YTAPHRVLA	TVYNGECRYN	RNAVPNLRGDL	Q V O1K.PRO
101	TTNPTAYHKA	APLTRLALE	YTAPHRVLA	TVYNGNCKYG	ESPVTNVRGDL	Q V RUSS.PRO
					ESPVTNVRGDL	
					DGTVANVRGDL	
101	TTNPTAYHK	APLTRLALI	YTAPHRVLA	T V Y N G N C K Y G	ESPVTNVRGDL	Q V UKG.PRO



pecoration 'AA1': Box residues that differ from the Consensus.

Figure 5. Amino acide alignment of FMDV VP1. Boxes are residues that differ among the compared VP1 sequence

					Perce	ent Sim	ilarity						_
	1	2	3	4	8	6	7	8	9_	10	11		
1		100.0	97.7	95.3	97.7	94.0	88.7	98.1	96.7	94.9	98.1	1	BAHRAIN.PRO
2	0.0		97.7	95.4	97.7	94.0	88.7	98.2	96.7	95.0	98.2	2	EMARAT.PRO
3	2.4	2.4		95.8	97.7	93.9	86.9	98.1	96.7	94.8	98.1	3	GEORGIA.PRO
4	4.8	4.7	4.3		95.4	93.1	86.9	95.9	94.4	95.4	95.9	4	INDIA.PRO
6	1.4	1.4	1.4	3.8		94.5	86.9	98.6	97.2	94.9	98.8	5	IRQ.PRO
8	5.6	5.8	5.8	8.1	4.1		88.7	95.9	93.5	95.0	95.9	6	O1IRAN.PRO
7	11.2	11.2	13.3	13.3	12.4	11.3		88.3	85.9	87.3	88.3	7	O1K.PRO
8	1.9	1.9	1.9	4.2	0.5	3.6	11.7		97.7	96.3	100.0	В	RU\$S.PRO
9	1.9	1.9	1.9	4.3	0.5	4.7	13.0	1.0		94.0	97.7	9	SAU.PRO
10	5.2	5.2	5.2	4.7	4.3	4.1	12.2	3.6	4.8		96.3	10	TUR.PRO
11	1.9	1.9	1.9	4.2	0.5	3.6	11.7	0.0	1.0	3.8		11	UKG.PRO
	1	2	3	4	6	6	7		9	10	11]

Figure 6. Sequence pair distances of 11 FMDV O1 amino acid sequences

Discussion

Regular vaccination with the suitable vaccine strain is the basis of FMD control in Iran. Selection of vaccine strain needs accurate diagnostic procedure which able to detect of serotype and subtype; and also differentiate variants of a given serotype. It has been shown that nucleotide sequencing of the field viruses and comparison of

the sequences with that of others for evaluation of the relationship degree between different viral strain may help to select a suitable vaccine strain in FMD controling program (Tulasiram et al 1997).

In this approach, we detect the nucleotide and amino acid sequences of the VP1 encoging region of O₁/Iran, and examine the relationship of the serotype to other FMDV O isolates. The sequencing of PCR products indicate that all products were FMDV-specific. The computer program Dnasis analyzing data on detection of restriction enzyme sites was shown that there was one one conserved *BstE*II site at position 436 which was also seen in in all O₁ subtypes (Locher *et al* 1995) and may be considered as O₁ specific site and used for detection of O₁ serotype. The G+C content of PCR product of O₁/Iran was 55.74 % which coincides with the G+C content of VP1 of FMDV serotype O1 previously reported by Tulasiram *et al* (1997). The G+C content of that serotype was found to be above 50%.

Results of our study indicate that there are 24 amino acid substitutions in VP1 gene of O₁/Iran. The amino acids between 138-160 of VP1 constitute main antigenic domain of the virus (Acharya *et al* 1989) and the amino acid between 200-213 of VP1 have been shown to responsible for the cell attachment site on FMDV for BHK cells (Tulasiram *et al* 1997). Comparison of amino acid sequences was shown that 10 of 24 alteration in amino acid sequence of O₁/Iran were located at amino acid 138-160. Highly variable region of FMDV are located at amino acid 137-156 and 210-213 of VP1. X-ray crystallographic studies showed that both sites of VP1 are exposed on the surface of the virus and are proximal to each other (Acharya *et al* 1989). Several lines of evidence suggest that 133-158 amino acid of VP1 of FMDV is highly immunodominant, perhaps due to its accessibility and structural flexibility (Acharya *et al* 1989, Logan *et al* 1993, Strohmaier *et al* 1982). Peptides representing this VP1 segment are necessary to afford protection by synthetic vaccine formulation (Bittle *et al* 1982, Dimarchi *et al* 1986, 1988). Therefor O₁/Iran carries subtype specific amino acid in main antigenic domain of VP1 that was located on

both sides of Arg-Gly-Asp (RGD) motif. This sequence creates the VP1 GH-loop (Acharya et al 1989, Logan et al 1993, Strohmaier et al 1982). The specific O₁/Iran amino acid sequence in the GH-loop is probably responsible for the antigenic response of this virus.

In conclusion, clearly, a better understanding of antigenic variation among the circulating FMDV field isolates using molecular techniques is neccessary for selecting suitable vaccine strain (s) to control of the disease. Here, we have determined the nucleotide and amino acid sequences of the VP1 of O₁/Iran genome, however, more studies depend on nuclotide sequence analysis of other citculating FMDV types are required for the production of an effective vaccine.

Acknowledgements

The authors wish to thank Dr. Z.Fayazi for sequence determination of VP1 gene and also the personel of Biothecnology and FMDV departments, Razi Institute.

References

Acharya, R., Fry, E., Stuart, D., Fox, G., Rowlands, D. and Brow, F. (1989). The three-dimensional structure of foot-and-mouth disease virus at 2.9A° resolution. *Nature* 337:709-716.

Beck, E., Strohmaier, K. (1987). Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. *Journal of Virology*. 61:1621-1629.

Bittle, J.L., Houghton, R.A., Alexander, H., Shinnick, T.M., Stucliff, J.G. and Lerner, R.A. (1982). Protection against foot-and-mouth disease virus by immunization with a chemically synthesized peptide from the viral nucleotide sequence. *Nature* 298:30-33.

Callens, M., Clercq, K. (1997). Differentiation of the seven serotype of footand-mouth disease virus by reverse transcriptase polymerase chain reaction. *Journal of Virological Method* 67:35-44. Dimarchi, R.D., Brooke, G.S. (1988). Synthetic vaccine for foot-and-mouth disease. *US patent* No: 4732971.

Dimarchi, R., Brooke, G., Golec, C., Cracknell, V., Doel, T. and Mowat, N. (1986). Protection of cattle against foot-and-mouth disease by a synthetic peptide. *Science* 239:639-641.

Dopazo, J., Sobrino, F., Polma, E. and Domingo, E. (1988). Gene encoding capsid protein VP1 of foot-and-mouth disease virus: Aquasispecies model of molecular evolution. *Proceeding of National Academic Science*. USA.65:6811-6815.

Grubman, M.J., Lewis, S.A. and Morgan, D.C. (1993). Protection of swine against foot-and-mouth disease virus capsid proteins expressed in heterologous system. *Vaccine* 11:825-829.

Kurz, C., Fross, F., kupper, H.K., Strohmaier, K. and Schaller, H., (1981). Nucleotide sequence and corresponding amino acid sequence of the gene for the major antigen of foot-and-mouth disease. *Nucleic Acid Research* 9:1919-1931.

Locher, F., Suryanarayana, V.V. S. and Tratschin, J.D. (1995). Rapid detection and characterization of foot-and-mouth disease by restriction enzyme and nucleotide sequence analysis of PCR. *Journal of Clinical Microbiology* 33:440-444.

Logan, D., Ghotaleh, R.A., Blakemore, W., Carry s., Jacjson, T., King, A., Lea, S., Lewis, R., Newman, J., Parry, N., Rowlands, D., Stuart, D. and Fry, E. (1993). Structure of a major immunogenic site on Foot-and-Mouth disease virus. *Nature* 362:566-568.

Masoudi, S., Mohammadi, A.A., Mahboudi, F., Roustaei, M.H. and Khedmati, K. (2000). Molecular cloning of VP1 gene of foot-and-mouth disease virus type O₁ /Iran. *Archives of Razi Institute* 51:1-14.

Murphy, A.F., Gibbs, E.P.J., Horzinek, M.C. and Studdert, M.J. (1999). Picornaviridae. In: *Veterinary Virology*. (3rd edn.). Pp:517-528. Academic Press, London.

Reid, S.M., Forsyth, M.A., Hutchings, G.H. and Ferris, N.P. (1998). Comparison of reverse transcription polymeras chain reaction, enzyme linked

immunosorbent assay and virus isolation for the routine diagnosis of foot-and-mouth disease. *Journal of Virology Method* 70: 213-217.

Rueckert, R.R. (1996). Picornaviridae: The viruses and their replication. In: B.N. Fields (Ed.), *Fields Virology*. (3rd edn.), P:618. Raven Press, Philadelphia.

Sambrook, J., Maniatis, T. and Fritsch, E.F. (1989). *Molecular Cloning, A Laboratory Manual (2nd edn.)*, Cold Spring Harbor Press, Cold Spring Harbor, NY.

Stram, Y., Laor, O., Molad, T., Chai, D., Moore, D., Yadin, H. and Becker, Y. (1994). Nucleotide sequence of the P1 region of serotype Asia1 foot-and-mouth disease virus. *Virus Gene* 8:275-278.

Strohmaier, K., Franze, R. and Adam, K. H. (1982). Location and characterization of the antigenic portion of the foot-and-mouth disease virus immunizing protein. *Journal of General Virology* 59:295-306.

Tulasiram, P., Tyagi, M., Srinivas, K., Prabhudas, K., Natarajan, C. and Suryanarayana, V. (1997). Antigenic variation in foot-and-mouth disease virus type Asia 1 isolate circulated during 1993-1995 in India. *Virus Gene* 15:247-25.